<span>How Covid-19 is accelerating adoption of decentralized clinical trials</span>
June 11, 2020

How Covid-19 is accelerating adoption of decentralized clinical trials

Medable and LabCorp CRO Covance signed a deal to accelerate adoption of decentralized trials, a trend that has been helped along as COVID-19 has created challenges to conducting trials dependent on traditional brick-and-mortar sites.LabCorp, the lab-testing giant, said May 28 that its CRO, Covance, would partner with Medable, a company that makes software
Read more »
<span>Novel Method Development Issues Observed for an IgG4-Based Therapeutic</span>
June 15, 2020

Novel Method Development Issues Observed for an IgG4-Based Therapeutic

WRIB 2020 -- IgG4-based therapeutics are a small but growing class of monoclonal antibodies employed for various patient treatments. The unique structure of the IgG4 molecule minimizes antibody and complement-dependent cytotoxicity, making it ideal for specific therapeutic purposes where 'silencing' of a target protein is required.

Read more »
<span>Combined Focal Radiation and Immune Checkpoint Inhibition Enhances Anti-Tumor Responses over Single Agent Treatment in a Murine Mammary Carcinoma Model</span>
June 22, 2020

Combined Focal Radiation and Immune Checkpoint Inhibition Enhances Anti-Tumor Responses over Single Agent Treatment in a Murine Mammary Carcinoma Model

AACR 2020 -- Tumor models can be generally divided into immunologically 'cold' and 'warm' categories based on their immune cell infiltrates and their ability to respond to checkpoint inhibition. 'Warm' tumors respond well to immuno-therapies while 'cold' tumors do not. Researchers are searching for ways to make 'cold' tumors more responsive.
Read more »
<span>Characterization of the Orthotopic MMTV-PyMT Murine Mammary Carcinoma Model Following Radiation and Immune Checkpoint Blockade</span>
June 22, 2020

Characterization of the Orthotopic MMTV-PyMT Murine Mammary Carcinoma Model Following Radiation and Immune Checkpoint Blockade

AACR 2020 -- The continual pressure to develop molecules that target the immune system requires that there are new, reliable and well-characterized preclinical models available. The characterization of these models must go beyond simple growth kinetics, and define the baseline immune profile in order for the models to be used to their fullest potential.
Read more »